RecruitingPhase 2NCT06679634

Retinoblastoma Phase II Expanded Access Clinical Trial

Studying Hereditary retinoblastoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Targeted Therapy Technologies, LLC
Intervention
Chemoplaque also referred to as Episcleral Topotecan(drug)
Enrollment
30 enrolled
Eligibility
8 years · All sexes
Timeline
2025 – 2028

Study locations (1)

Collaborators

Morgan Stanley Children's Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06679634 on ClinicalTrials.gov

Other trials for Hereditary retinoblastoma

Additional recruiting or active studies for the same condition.

See all trials for Hereditary retinoblastoma →

← Back to all trials